Patent Loophole Brings Cystic Fibrosis Drug at 96% Off

A legal exemption in international patent law is enabling a generic version of Vertex Pharmaceuticals’ blockbuster cystic fibrosis drug Trikafta to be manufactured in Bangladesh and sold for roughly 96% less than the US price, offering a lifeline to thousands of patients in developing countries who have been priced out of treatment.

The generic drug, branded Triko, is produced by Beximco Pharmaceuticals and will cost $12,775 per year for adults and $6,387.50 for children — compared to Vertex’s US list price of $325,300 to $370,000 annually. The initiative is coordinated through a patient-led “CF Buyers’ Club” that began distributing the drug in spring 2026, according to STAT News.

The Legal Loophole

Bangladesh is classified as a Least Developed Country (LDC) by the World Trade Organization and is exempt from enforcing pharmaceutical patents under the TRIPS (Trade-Related Aspects of Intellectual Property Rights) Agreement. This exemption, originally designed to allow LDCs to build their pharmaceutical industries, permits Beximco to legally manufacture and export generic versions of patented drugs without facing patent infringement claims.

As Down To Earth notes, Bangladesh is the only one of 44 LDCs to have effectively used these TRIPS flexibilities to build a thriving pharmaceutical industry. The country’s sector was radically reformed after independence in 1971 and is now noted for having a superior regulatory regime compared to India, which has faced scandals over toxic cough syrups and regulatory failures.

A Crisis of Access

Cystic fibrosis is a rare, inherited genetic condition that causes progressive damage to the lungs and digestive system. Patients have a mutation in the CFTR gene, leading to thick, sticky mucus buildup that causes severe respiratory infections and significantly shortened life expectancy — often under 20 years in developing countries without treatment.

Trikafta (elexacaftor/tezacaftor/ivacaftor), approved by the FDA in October 2019, is a triple-combination therapy that targets the underlying protein defect. It has been described as a “miracle drug” because it can normalize life expectancy for eligible patients. Yet according to The Guardian, of an estimated 162,000 people living with cystic fibrosis globally, only 12% currently receive triple-combination therapy. Only one low- or middle-income country offers reimbursement for Trikafta, compared with 35 high-income nations.

The Buyers’ Club Model

The CF Buyers’ Club was formed in Seattle in October 2025 at the North American Cystic Fibrosis Conference by patient advocacy groups including Right to Breathe, Just Treatment, Third World Network, and Health Justice Initiative. It operates as a community-led distribution network for patients in countries where Vertex’s drug is unaffordable or unavailable.

“This is a historic moment,” said Gayle Pledger, who heads the Right to Breathe campaign in the UK, in a statement. “We’ve watched children suffer and die while a treatment sat on the shelf, priced out of reach. Today, that changes. We’ve proven that patient power can change what billion-dollar corporations refuse to.”

The cost differential is staggering: Beximco’s product allows 58 children to be treated for the same cost as a single patient on Vertex’s formulation. The World Health Organization recently classified Trikafta’s active ingredients as essential medicines, underscoring their clinical importance.

The Human Toll

For patients like Cheri Nel, a 39-year-old South African CF patient and activist, the fight for access has been deeply personal. Nel filed a landmark lawsuit against Vertex in South Africa alleging patent abuse and violation of patients’ constitutional rights. “Any person that dies from today — that’s on you,” she told The Guardian.

Nel, who has been importing a generic version from Argentina through an informal WhatsApp-based buyers’ club, described the drug’s impact: “I wake up in the mornings now [and] I don’t have a sinus headache. I don’t cough a lot any more. I don’t have to take a lot of headache medication to deal with my sinuses.”

Tanya Koorts, a South African mother whose seven-year-old son Janco now takes the generic medication, said: “Each breath matters. I will fight for the cystic fibrosis community. They deserve to live.”

Vertex’s Position

Vertex Pharmaceuticals derives the vast majority of its revenue from Trikafta and related CF drugs. In 2024, the company’s revenue crossed $11.02 billion. The CF Buyers’ Club notes that Trikafta generated $29.5 billion in revenue from 2012 to 2021.

In a statement to The Guardian, a Vertex spokesperson said: “We believe in the importance of upholding intellectual property rights to drive innovation in tackling the unmet medical needs across the world. At Vertex, we have worked tirelessly for over 20 years to design, discover and develop CF medicines to treat the underlying cause of the disease. Patents provide the necessary incentives to drive research and development investments in areas of unmet medical needs.”

What’s Next

The initiative represents one of the most consequential challenges to pharmaceutical monopoly power in rare diseases. However, the window for this model may be limited: Bangladesh is scheduled to graduate from LDC status, and its TRIPS patent waiver is expected to end in 2026 or shortly thereafter, creating urgency around the current opportunity for generic production.

It remains to be seen how Vertex will respond legally to Beximco’s generic production, whether the CF Buyers’ Club will face legal challenges, and whether this model can be scaled to other expensive patented drugs. For now, thousands of CF patients in low- and middle-income countries have a new source of hope — one that costs a fraction of the price.